Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive

Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.

52/435 Coincidencias para
“biomarker standardization”

“biomarker standardization” Borrar todo
  1. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication

    Poynard T et al. · Clin Chem · 2007 Coinc. 100

    …to elaborate simple methods of standardization. ### Methods The AUCs of FibroTest (FT…

    FibroTest HCV

  2. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Coinc. 100

    …Furthermore, NAFLD diagnosis relied exclusively on circulating biomarker-based liver scores, without…

    FibroTest NashTest SteatoTest Metabolic

  3. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Coinc. 99

    …After standardization of estimates, analyses used curve fitting, quantitative Lin concordance coefficient…

    ActiTest FibroTest SteatoTest Alcohol +3

  4. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007 Coinc. 98

    ### Background The area under the receiver operating characteristic (ROC) curve is widely…

    FibroTest HCV

  5. Meta-analyses of FibroTest diagnostic value in chronic liver disease. Key publication Meta Analysis

    Poynard T et al. · BMC Gastroenterol · 2007 Coinc. 97

    ### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…

    FibroTest Alcohol HBV HCV +1

  6. Biomarkers of liver fibrosis. Review

    Poynard T et al. · Adv Clin Chem · 2008 Coinc. 96

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  7. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

    Morra R et al. · Hepatology · 2008 Coinc. 95

    FibroTest HCV

  8. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.

    Rosenthal-Allieri MA et al. · Gastroenterol Clin Biol · 2007 Coinc. 94

    ### Objectives Combination of alpha 2-macroglobulin, haptoglobin, apolipoprotein-A1, gamma-glutamyl transpeptidase…

    ActiTest FibroTest HCV

  9. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

    Vallet-Pichard A et al. · Hepatology · 2007 Coinc. 93

    ### Unlabelled To optimize the management of patients with chronic hepatitis C virus…

    FibroTest HCV

  10. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Coinc. 92

    A serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and…

    FibroTest HBV

  11. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Coinc. 91

    …As waiting for the perfect biomarker for the diagnosis of advanced fibrosis…

    ActiTest FibroTest SteatoTest Alcohol +5

  12. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

    Munteanu M et al. · J Hepatol · 2011 Coinc. 90

    FibroTest HBV HCV HIV

  13. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication

    Deckmyn O et al. · Biomedicines · 2022 Coinc. 89

    …the “Control Population”, which enabled standardization of protein serum levels according to…

    FibroTest Metabolic

  14. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Meta Analysis

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Coinc. 88

    ### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…

    ActiTest HCV

  15. FibroMAX: towards a new universal biomarker of liver disease? Review

    Morra R et al. · Expert Rev Mol Diagn · 2007 Coinc. 87

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  16. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis

    Poynard T et al. · PLoS One · 2012 Coinc. 86

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  17. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Coinc. 85

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  18. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Coinc. 84

    FibroTest has been validated as a biomarker of fibrosis in patients with…

    ActiTest AshTest FibroTest Alcohol

  19. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009 Coinc. 83

    FibroTest HCV

  20. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Coinc. 82

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  21. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Coinc. 81

    ### Background The prediction of fibrosis is an essential part of the assessment…

    FibroTest HCV

  22. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014 Coinc. 80

    FibroTest HBV

  23. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Coinc. 79

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  24. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Coinc. 78

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  25. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis

    Salkic NN et al. · Am J Gastroenterol · 2014 Coinc. 77

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  26. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.

    Mallet V et al. · Aliment Pharmacol Ther · 2009 Coinc. 76

    ### Background The Fib-4 index is a simple and inexpensive biomarker to…

    FibroTest HBV

  27. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Coinc. 75

    ### Background Previous research has shown variation in the effects of patient factors…

    FibroTest HCV

  28. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Coinc. 75

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  29. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Coinc. 74

    ### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…

    FibroTest NashTest SteatoTest Metabolic

  30. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Coinc. 73

    ### Introduction Recently, a study showed that Controlled Attenuation Parameter (CAP), evaluated with…

    SteatoTest Metabolic

  31. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

    Bottero J et al. · J Hepatol · 2009 Coinc. 72

    …for the evaluation of serum biomarker performance. The AUROCs of the Fibrotest…

    FibroTest HBV HIV

  32. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Coinc. 71

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  33. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Coinc. 70

    ### Background There is a clear need for better biomarkers of drug-induced…

    ActiTest FibroTest Other

  34. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication

    Poynard T et al. · Diagnostics (Basel) · 2025 Coinc. 69

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  35. Noninvasive evaluation of NAFLD. Review

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Coinc. 68

    A common clinical concern in patients with NAFLD is whether they have…

    ActiTest FibroTest NashTest SteatoTest +1

  36. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Coinc. 67

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  37. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis

    Houot M et al. · Aliment Pharmacol Ther · 2016 Coinc. 66

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  38. Non-invasive markers for hepatic fibrosis. Review

    Baranova A et al. · BMC Gastroenterol · 2011 Coinc. 65

    …Current non-invasive methods range from serum biomarker assays to advanced imaging…

    FibroTest Alcohol HBV HCV +3

  39. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Coinc. 64

    ### Objective There is a controversy about the performance of blood tests for…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  40. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Coinc. 63

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  41. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Key publication

    Poynard T et al. · Gastro Hep Adv · 2022 Coinc. 62

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 HBV

  42. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Coinc. 61

    ### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…

    ActiTest FibroTest HCV

  43. Noninvasive diagnosis in alcohol-related liver disease.

    Hadefi A et al. · Health Sci Rep · 2020 Coinc. 60

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  44. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. Review

    Stasi C et al. · World J Gastroenterol · 2016 Coinc. 59

    The assessment of the fibrotic evolution of chronic hepatitis has always been…

    FibroTest HCV

  45. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Coinc. 58

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  46. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Coinc. 57

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  47. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Coinc. 56

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  48. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Coinc. 55

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  49. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Coinc. 54

    FibroTest Alcohol HBV HCV +3

  50. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Coinc. 53

    FibroTest Alcohol

  51. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection

    · 2015 Coinc. 52

    These are the first World Health Organization (WHO) guidelines for the prevention…

    FibroTest HBV

  52. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Coinc. 51

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.